[go: up one dir, main page]

UA101140C2 - Комбинация рекомбинантной микобактерии и биологически активного агента как вакцины - Google Patents

Комбинация рекомбинантной микобактерии и биологически активного агента как вакцины

Info

Publication number
UA101140C2
UA101140C2 UAA200704420A UAA200704420A UA101140C2 UA 101140 C2 UA101140 C2 UA 101140C2 UA A200704420 A UAA200704420 A UA A200704420A UA A200704420 A UAA200704420 A UA A200704420A UA 101140 C2 UA101140 C2 UA 101140C2
Authority
UA
Ukraine
Prior art keywords
combination
active agent
biologically active
constituent
vaccine
Prior art date
Application number
UAA200704420A
Other languages
English (en)
Ukrainian (uk)
Inventor
Альбрехт Лойфер
Бернд АЙЗЕЛЕ
Леандер Гроде
Original Assignee
Вакцине Проект Мениджмент Гмбх
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Вакцине Проект Мениджмент Гмбх filed Critical Вакцине Проект Мениджмент Гмбх
Publication of UA101140C2 publication Critical patent/UA101140C2/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A61K39/005—Trypanosoma antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55544—Bacterial toxins
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Изобретение относится к комбинации для применения в способе вызывания ТН1 иммунного ответа, которая содержит первую составляющую и отдельно вторую составляющую. Первой составляющей является бактериальная клетка, которая включает по крайней мере одну молекулу рекомбинантной нуклеиновой кислоты, которая кодирует фаголизосомальный ускользающий пептид или полипептид. Бактериальной клеткой является дефицитная по уреазе клетка Mycobacterium. Второй составляющей является биологически активный агент, который вызывает иммунный ответ.
UAA200704420A 2004-10-21 2005-10-16 Комбинация рекомбинантной микобактерии и биологически активного агента как вакцины UA101140C2 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP04025096A EP1649869A1 (en) 2004-10-21 2004-10-21 Combination of a recombinant mycobacterium and a biologically active agent as a vaccine
PCT/EP2005/011127 WO2006045468A1 (en) 2004-10-21 2005-10-16 Combination of a recombinant mycobacterium and a biologically active agent as a vaccine

Publications (1)

Publication Number Publication Date
UA101140C2 true UA101140C2 (ru) 2013-03-11

Family

ID=35462399

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA200704420A UA101140C2 (ru) 2004-10-21 2005-10-16 Комбинация рекомбинантной микобактерии и биологически активного агента как вакцины

Country Status (17)

Country Link
US (1) US9078844B2 (ru)
EP (2) EP1649869A1 (ru)
JP (1) JP4836957B2 (ru)
KR (1) KR101300905B1 (ru)
CN (1) CN101048178B (ru)
AU (1) AU2005298976A1 (ru)
BR (1) BRPI0517003B1 (ru)
CA (1) CA2584321C (ru)
DK (1) DK1802340T3 (ru)
ES (1) ES2524921T3 (ru)
MX (1) MX2007004734A (ru)
PL (1) PL1802340T3 (ru)
PT (1) PT1802340E (ru)
RU (1) RU2495677C2 (ru)
SI (1) SI1802340T1 (ru)
UA (1) UA101140C2 (ru)
WO (1) WO2006045468A1 (ru)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA012434B1 (ru) 2004-12-01 2009-10-30 ЭЙРАС ГЛОУБАЛ ТиБи ВЭКСИН ФАУНДЕЙШН Рекомбинантные штаммы bcg, обладающие повышенной способностью к высвобождению из эндосомы
US8741313B2 (en) 2008-01-11 2014-06-03 Emory University Polypeptide vaccine and vaccination strategy against mycobacterium
KR101907222B1 (ko) * 2010-09-20 2018-10-11 바크지네 프로제크트 마나게멘트 게엠베하 인간에게 사용하기 위한 백신으로서 재조합 마이코박테리움
LT2654783T (lt) * 2010-12-21 2016-11-25 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Rekombinantinė mikobakterija kaip vakcina
WO2013039069A1 (ja) 2011-09-13 2013-03-21 日本ビーシージー製造株式会社 新規な組換えｂｃｇワクチン
EP3090757A1 (en) * 2015-05-04 2016-11-09 Vakzine Projekt Management GmbH Recombinant mycobacterium as an immunotherapeutic agent for the treatment of cancer
US12491216B2 (en) 2018-12-04 2025-12-09 Neiker—Instituto Vasco De Investigacion Y Desarrollo Agrario, S.A. Immunostimulant for use against pathogens
US20230218684A1 (en) * 2020-03-30 2023-07-13 North Carolina State University Engineered bacteria for use in vaccine compositions
CN113499439B (zh) * 2021-07-20 2023-03-17 上海市肺科医院 结核菌UreC蛋白在制备抗结核分枝杆菌药物中的应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050169900A1 (en) * 1993-02-17 2005-08-04 Sloan Kettering Institute For Cancer Research Allogeneic vaccine and methods to synthesize same
ATE248914T1 (de) * 1993-02-17 2003-09-15 Sloan Kettering Inst Cancer Allogenes vakzin und synthesemethode für selbiges
DE19640817A1 (de) * 1996-10-02 1998-05-14 Hermann Prof Dr Bujard Rekombinantes Herstellungsverfahren für ein vollständiges Malaria-Antigen gp190/MSP 1
EP0902086A1 (en) * 1997-08-22 1999-03-17 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Tuberculosis vaccine
DE19910044A1 (de) * 1999-03-08 2000-09-14 Bodo Plachter Virale Partikel, die nach Infektion durch humanes Cytomegalovirus freigesetzt werden und ihre Verwendung als Impfstoff
EP1158991A4 (en) * 1999-03-15 2003-05-14 Malaghan Inst Of Medical Res ASTHMA TREATMENT
SI1618128T1 (sl) * 2003-04-23 2010-11-30 Max Planck Gesellschaft Cepivo proti tuberkolozi z izboljšano učinkovitostjo
US7855268B2 (en) * 2006-06-01 2010-12-21 Allergan, Inc. Tolerogizing compositions comprising botulinum toxin type B peptides
US7670788B2 (en) * 2006-06-01 2010-03-02 Allergan, Inc. Determining and reducing immunoresistance to a Botulinum toxin therapy using Botulinum toxin B peptides

Also Published As

Publication number Publication date
BRPI0517003B1 (pt) 2021-10-13
KR101300905B1 (ko) 2013-08-27
JP2008517013A (ja) 2008-05-22
CA2584321C (en) 2021-06-15
DK1802340T3 (en) 2014-12-01
JP4836957B2 (ja) 2011-12-14
EP1802340B1 (en) 2014-09-03
CN101048178A (zh) 2007-10-03
BRPI0517003A (pt) 2008-09-30
EP1649869A1 (en) 2006-04-26
SI1802340T1 (sl) 2015-01-30
PT1802340E (pt) 2014-12-09
MX2007004734A (es) 2007-07-13
EP1802340A1 (en) 2007-07-04
KR20070068398A (ko) 2007-06-29
CA2584321A1 (en) 2006-05-04
US20080292656A1 (en) 2008-11-27
WO2006045468A1 (en) 2006-05-04
RU2495677C2 (ru) 2013-10-20
AU2005298976A1 (en) 2006-05-04
US9078844B2 (en) 2015-07-14
CN101048178B (zh) 2012-09-05
RU2007118675A (ru) 2008-11-27
PL1802340T3 (pl) 2015-03-31
HK1106929A1 (en) 2008-03-20
ES2524921T3 (es) 2014-12-15

Similar Documents

Publication Publication Date Title
WO2005007818A8 (en) Exo-specific amylase polypeptides, nucleic acids encoding those polypeptides and uses thereof
WO2004099370A3 (en) NOVEL BACILLUS mHKcel CELLULASE
WO2006083276A3 (en) Interferon-alpha polypeptides and conjugates
PL1618128T3 (pl) Szczepionka przeciwko gruźlicy o ulepszonej skuteczności
AU2003244855A1 (en) Method to enhance an immune response of nucleic acid vaccination
UA103215C2 (ru) Полипептид с ксиланазной активностью
EP1530637A4 (en) SUBTILISIN CARLSBERG PROTEINS WITH REDUCED IMMUNOGENICITY
WO2004046365A3 (en) Interferon-alpha polypeptides and conjugates
UA101140C2 (ru) Комбинация рекомбинантной микобактерии и биологически активного агента как вакцины
ATE551069T1 (de) Mucin-fusionspolypeptid-vakzine, zusammensetzungen und ihre verwendung
WO2004087874A3 (en) Novel nucleic acids and polypeptides
DE60118359D1 (de) Humanische pellino-polypeptide
DE602004028266D1 (de) Angiogene peptide und ihre verwendungen
NZ334839A (en) Polynucleotide molecules encoding neospora proteins and uses thereof
NZ603854A (en) West nile virus vaccine
WO2003093298A3 (en) Immunogenic peptides
AU2014210617B2 (en) Combination of a recombinant mycobacterium and a biologically active agent as a vaccine
WO2007045019A3 (en) Polyoleosins
SG146640A1 (en) Isolated photoprotein mtclytin, and use thereof
WO2004033706A3 (en) Nucleic acids encoding duramycin
WO2003089462A3 (en) Tuberculosis vaccines including recombinant bcg strains expressing alanine dehydrogenase, serine dehydratase and/or glutamine synthetase
WO2005072766A3 (en) Peptides that bind to hsp90 proteins
WO2002062964A3 (en) Ap1 amine oxidase variants
GB0409559D0 (en) Polypeptide
WO2006060484A3 (en) Tuberculosis nucleic acids, polypeptides and immunogenic compositions